Progress on pathogenesis and treatment of ocular cicatricial pemphigoid
10.3980/j.issn.1672-5123.2022.1.11
- VernacularTitle:眼瘢痕性类天疱疮机制及治疗研究进展
- Author:
Zhuo-Ya Quan
1
Author Information
1. <sup>1</sup>Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Medical University, Xi'an 710038, Shaanxi Province, China|<sup>2</sup>Department of Ophthalmology, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi Province, China|<sup>3</sup>Department of Ophthalmology, Fufeng County People's Hospital, Fufeng 722200, Shaanxi Province, China
- Publication Type:Review
- Keywords:
ocular cicatricial pemphigoid;
cytokines;
genes;
immunosuppressants;
adrenal cortex hormones
- From:
International Eye Science
2022;22(1):57-61
- CountryChina
- Language:Chinese
-
Abstract:
Ocular cicatricial pemphigoid(OCP)is a special manifestation of mucosal pemphigoid(mucous membrane pemphigoid, MMP), and the pathogenesis is not clear at present. It can be caused by variety factors such as antigen-antibody reaction, inflammation cell infiltration, the action of various cytokines, elevated calcium ion levels and susceptibility genes. In the early period of diseases, conjunctival present chronic progressive fibrotic inflammation, later the corneal opacity and the neovascularization will eventually lose vision. Therefore, it is particularly important to carry out clinical standardized treatment for OCP patients in a timely manner. To use medicine to control the inflammation and delay the progression of the disease, for example, dapsone, intravenous immunoglobulin(IVIG), rituximab(RTX), tumor necrosis factor antagonists and adrenocorticoids. Surgical treatment can be considered appropriately when OCP patients are complicated by severe trichiasis, corneal disease and cataract.
- Full text:202201011.pdf
